Wrong signals for drug supply and Germany as a location

01.08.2016 14:43

The pharmaceutical and technology associations are irritated by the draft bill presented by the Federal Ministry of Health (BMG), which includes market interventions that were never discussed in the pharmaceutical dialogue. These include, for example, the extension of the price moratorium and options for exclusions from reimbursement for approved medications.

The draft addresses other points, such as the regulations for the reimbursement of accompanying diagnostics and the improvement of planning in discount agreements, but the concrete design lacks the necessary clarity, the associations emphasize. In this form, no improvement in drug supply can be achieved.

Counterproductive signals for Germany as a business location are also the restriction on free pricing and a sales threshold in the first year, which represent a significant additional intervention in an already thoroughly regulated market. Reliable framework conditions are essential for good patient care and solid economic development in Germany as a healthcare, research and business location.